LNTH vs. NEOG, QDEL, RIOT, NTLA, CLDX, MYGN, PRGO, IOVA, MMSI, and INSM
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Neogen (NEOG), QuidelOrtho (QDEL), Riot Platforms (RIOT), Intellia Therapeutics (NTLA), Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), Perrigo (PRGO), Iovance Biotherapeutics (IOVA), Merit Medical Systems (MMSI), and Insmed (INSM).
Neogen (NASDAQ:NEOG) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.
Neogen received 5 more outperform votes than Lantheus when rated by MarketBeat users. However, 65.13% of users gave Lantheus an outperform vote while only 57.29% of users gave Neogen an outperform vote.
Neogen currently has a consensus target price of $23.50, indicating a potential upside of 55.94%. Lantheus has a consensus target price of $104.14, indicating a potential upside of 84.26%. Given Neogen's stronger consensus rating and higher probable upside, analysts clearly believe Lantheus is more favorable than Neogen.
Neogen has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
96.7% of Neogen shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.7% of Neogen shares are owned by company insiders. Comparatively, 1.5% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Lantheus has higher revenue and earnings than Neogen. Lantheus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
Lantheus has a net margin of 25.20% compared to Lantheus' net margin of 1.28%. Neogen's return on equity of 63.16% beat Lantheus' return on equity.
In the previous week, Neogen and Neogen both had 5 articles in the media. Neogen's average media sentiment score of 1.39 beat Lantheus' score of 0.77 indicating that Lantheus is being referred to more favorably in the news media.
Summary
Lantheus beats Neogen on 13 of the 17 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Lantheus Competitors List
Related Companies and Tools